StockData
CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Contineum Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.44+0.36 (+5.08%)

Close on Oct 19, 2026

Market cap
$278.76M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Oct 29, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 30, 2026After market close–––
Q1 FY2026
Ended Mar 31, 2026
May 5, 2026After market close–––
Q4 FY2025
Ended Dec 31, 2025
Mar 5, 2026After market close–$-0.49–
Q3 FY2025
Ended Sep 30, 2025
Oct 30, 2025After market close–$-0.45–
Q2 FY2025
Ended Jun 30, 2025
Aug 5, 2025After market close–$-0.62–
Q1 FY2025
Ended Mar 31, 2025
May 14, 2025After market close–$-0.62–
Q4 FY2024
Ended Dec 31, 2024
Mar 6, 2025After market close–$-0.56–
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024After market close–––
Q2 FY2024
Ended Jun 30, 2024
Aug 13, 2024After market close–$-0.39–
Q1 FY2024
Ended Mar 31, 2024
May 16, 2024After market close–$-3.55–

Press releases

Announcements Contineum Therapeutics filed with the SEC